Sign inJoin waitlistJoin the waitlist

Andrew Kent

Assistant Professor · University of Colorado School of Medicine

Credentials: · · · ·

History

University of Colorado School of Medicine
Present
CU Anschutz
Present

Hematology and Medical Oncology
CU
2021–2024
Internal Medicine
CU
2018–2021
Mount Sinai
Icahn School of Medicine at Mount Sinai
2014–2018

Research

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
Blood Advances · 2022 · 61 citations
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse
Bone Marrow Transplantation · 2023 · First of 11 authors · 47 citations
Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML
Review · Frontiers in Immunology · 2023 · First of 3 authors · 25 citations

Daniel Pollyea
18 papers
Maria Amaya
12 papers
Christine McMahon
11 papers
Jon Gutman
11 papers
Marc Schwartz
10 papers
Clayton Smith
6 papers
Jeffrey Schowinsky
3 papers
Mathew Angelos
3 papers
Justin Watts
2 papers
Kellen Gil
2 papers
MC
Megan Connor
2 papers · 2 as a resident
Zenggang Pan
2 papers

Clinical trials

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1
University of Colorado, Denver
2024–2027
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
Sub-investigator · Recruiting · Phase 2
University of Colorado, Denver
2026–2030